Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2023-08-22 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
关于使用部分闲置募集资金购买理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the use of part of idle raised funds to purchase financial products. It details the raised funds, their usage, the decision-making process by the board and supervisory committee, independent director opinions, and risk control measures. The document is a formal disclosure about the company's financing fund usage and investment decisions, specifically about idle raised funds and their investment in financial products. It does not contain financial statements or comprehensive financial data, nor is it a report like an annual or interim report. It is not a call transcript, earnings release, or management report. It is an update on capital usage and financing activities related to raised funds. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 3474 characters, which is consistent with an announcement rather than a full report. Confidence is high given the clear focus on fundraising and capital usage.
2023-08-22 Chinese
2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告 2023" which translates to "Half-Year Report 2023". It contains detailed financial data such as revenue, profit, assets, liabilities, and operational performance for the period January 1, 2023 to June 30, 2023. The document includes sections on accounting data, business overview, risk analysis, financial analysis, and other comprehensive financial and operational information. It explicitly states it is a half-year report and includes actual financial statements and substantive financial data. The length of the document is about 15,000 characters, indicating it is a full report rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-22 Chinese
2023年半年度报告披露提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (336 characters) indicating that the company's 2023 half-year report and summary have been disclosed on the official exchange platform. It explicitly states that the report is available elsewhere and investors should refer to it. There is no substantive financial data or detailed report content included here. According to the 'Menu vs Meal' rule, this is a report publication announcement rather than the report itself.
2023-08-22 Chinese
2023年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023 Half-Year Special Report on the Deposit and Actual Use of Raised Funds" by Sichuan Zitonggong Pharmaceutical Co., Ltd. It details the amount of funds raised through a public stock issuance, the timing and amounts of funds received, the use of these funds, and the balance remaining as of June 30, 2023. It also includes information on the management of these funds, compliance with regulatory requirements, and specific investment projects funded by the raised capital. The document is a detailed report on the use of capital raised by the company, focusing on the management and deployment of these funds rather than a general financial report or earnings release. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is over 5,000 characters and contains substantive financial data related to fundraising and capital use, not merely an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2023-08-22 Chinese
第三届董事会第二十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 22nd meeting of the third board of directors of Sichuan Zitonggong Pharmaceutical Co., Ltd. It includes details about the meeting date, attendance, and voting results on several agenda items such as approval of the 2023 semi-annual report, a special report on the use of raised funds, and proposals related to the management of raised funds. The document does not contain the full semi-annual report or detailed financial statements but rather announces the board's approval of these reports and related matters. It also references that the full reports are disclosed on the Beijing Stock Exchange information platform. The document length is relatively short (2227 characters) and serves as a meeting resolution announcement rather than the report itself. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board decisions and management matters.
2023-08-22 Chinese
独立董事关于第三届董事会第二十二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at a specific board meeting, including a special report on the use of raised funds and approval of using idle raised funds for financial products. It references compliance with laws and regulations and provides an independent opinion rather than presenting full financial statements or detailed financial results. The document is short (961 characters) and focuses on governance and compliance opinions related to fundraising usage, not a full audit or annual report. It is not a report publication announcement or certification letter but an independent opinion related to board matters. This fits best under Board/Management Information (MANG), as it concerns board meeting matters and independent directors' opinions on company governance and fund usage.
2023-08-22 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.